title: A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
abstract: OBJECTIVE
  The aim of this study was to assess the efficacy and safety of the once-daily atomoxetine compared with placebo in pediatric patients with attention-deficit/hyperactivity disorder (ADHD) in Taiwan.
  
  
  METHODS
  The study sample included 106 patients aged 6-16 years who met the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria of ADHD randomly assigned to atomoxetine once daily (n = 72) and placebo once daily (n = 34) in a double-blind, 6-week treatment study. The primary efficacy measure was the total score of the ADHD Rating Scale-IV Parents Version: Investigator Administered and Scored. The secondary efficacy measures included the Clinical Global Impressions--ADHD--Severity and Chinese Conner's Parent and Teacher Rating Scale--Revised: Short Form. Data were analyzed on an intent-to-treat basis and a last-observation-carried-forward approach.
  
  
  RESULTS
  The two treatment groups did not differ in demographics and baseline measures. Compared to the placebo group, the atomoxetine group showed significantly greater reductions in ADHD-related symptoms according to the ratings of investigators, parents, and teachers. The treatment effect size of the primary efficacy measure was 0.70 at the end of study. Adverse events reported significantly more frequently with atomoxetine were decreased appetite (36.1%) and nausea (16.6%). No drug-related serious adverse event was observed.
  
  
  CONCLUSIONS
  Once-daily atomoxetine is an effective, well-tolerable, and safe treatment for children and adolescents with ADHD in Taiwan.
authors.affiliation: Department of Psychiatry, College of Medicine, National Taiwan Universiy, Taipei, Taiwan.
authors.forename: Susan S F
authors.initials: SS
authors.lastname: Gau
authors.forename: Yu-Shu
authors.initials: YS
authors.lastname: Huang
authors.forename: Wei-Tsuen
authors.initials: WT
authors.lastname: Soong
authors.forename: Miao-Chun
authors.initials: MC
authors.lastname: Chou
authors.forename: Wen-Jiun
authors.initials: WJ
authors.lastname: Chou
authors.forename: Chi-Yung
authors.initials: CY
authors.lastname: Shang
authors.forename: Wan-Ling
authors.initials: WL
authors.lastname: Tseng
authors.forename: Albert J
authors.initials: AJ
authors.lastname: Allen
authors.forename: Phil
authors.initials: P
authors.lastname: Lee
mesh_terms: D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001066:Appetite / Q000187:drug effects; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D002648:Child; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005178:Faculty; D005260:Female; D006801:Humans; D008297:Male; D009325:Nausea / Q000139:chemically induced; D010290:Parents; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D012720:Severity of Illness Index; D013624:Taiwan; D016896:Treatment Outcome